This segment focuses on the research, development, and clinical trials of therapies for Primary Biliary Cholangitis (PBC), a chronic liver disease. The lead product candidate, seladelpar, is a selective agonist of peroxisome proliferator activated receptor delta (PPARδ) and is currently in Phase III clinical trials. Research and development activities include conducting clinical trials to evaluate the efficacy and safety of seladelpar in PBC patients, as well as exploring its potential in other liver diseases. The technology platform centers around small molecule drug development and targeted therapies for liver diseases. The patient impact is significant, as PBC can lead to liver failure and the need for transplantation. Seladelpar aims to improve liver function and reduce the need for liver transplants. Market positioning is strong, with seladelpar potentially becoming a leading treatment for PBC. Future opportunities include expanding the use of seladelpar to treat other liver diseases. Regulatory and clinical aspects involve obtaining FDA approval and navigating the clinical trial process. Partnerships include a collaboration with Kaken Pharmaceutical Co., Ltd. for commercialization in Japan.

This segment encompasses research and development efforts focused on treating Nonalcoholic Steatohepatitis (NASH), a progressive liver disease characterized by inflammation and liver damage. CymaBay has completed a Phase 2b clinical study for seladelpar in NASH patients. The research involves investigating the mechanisms of action of seladelpar and its effects on liver inflammation, fibrosis, and other NASH-related complications. The technologies and methodologies employed include small molecule drug development, clinical trial design, and biomarker analysis. The therapeutic area is NASH, with the goal of reducing liver damage and improving patient outcomes. The patient impact is substantial, as NASH is a growing health concern with limited treatment options. Market positioning is competitive, with several companies developing NASH therapies. Future opportunities include advancing seladelpar through late-stage clinical trials and potentially obtaining regulatory approval. Regulatory and clinical aspects involve conducting clinical trials and working with regulatory agencies to ensure patient safety and drug efficacy. This segment is currently under Gilead's management after the acquisition.

This segment focuses on the development of MBX-2982, a Phase 2a clinical study for the treatment of hypoglycemia in type 1 diabetics. Research and development activities include conducting clinical trials to evaluate the efficacy and safety of MBX-2982 in managing blood sugar levels and reducing the frequency of hypoglycemic events. The technology platform centers around small molecule drug development and targeted therapies for metabolic diseases. The therapeutic area is hypoglycemia in type 1 diabetes, with the aim of improving glycemic control and reducing the risk of severe hypoglycemic episodes. The patient impact is significant, as hypoglycemia can lead to serious health complications. Market positioning is focused on addressing an unmet medical need in the diabetes treatment landscape. Future opportunities include advancing MBX-2982 through clinical development and potentially obtaining regulatory approval. Regulatory and clinical aspects involve conducting clinical trials and working with regulatory agencies to ensure patient safety and drug efficacy. This segment is currently under Gilead's management after the acquisition.